

		Ohasama Study				
19	Terata S, et al.	Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study	Journal of Hypertension	30	1632-38	2012
20	Hashimoto T, et al.	Home blood pressure level, blood pressure variability, smoking, and stroke risk in Japanese men: the Ohasama study	American Journal of Hypertension	25	883-891	2012
21	Arai H, Kokubo Y, Watanabe M, Sawamura T, Ito Y, Minagawa A, Okamura T, Miyamoto Y.	Small Dense Low-Density Lipoproteins Cholesterol can Predict Incident Cardiovascular Disease in an Urban Japanese Cohort: The Suita Study.	J Atheroscler Thromb.	20(2)	195-203	2013
22	Morisaki H, Yamanaka I, Iwai N, Miyamoto Y, Kokubo Y, Okamura T, Okayama A, Morisaki T.	CDH13 Gene Coding T-Cadherin Influences Variations in Plasma Adiponectin Levels in the Japanese Population.	Hum Mutat.	33(2)	402-10	2012
23	Saito I, Kokubo Y, Kiyohara Y, Doi Y, Saitoh S, Ohnishi H, Miyamoto Y.	Prospective study on waist circumference and risk of all-cause and cardiovascular mortality.	Circ J.	76 (12)	2867-74.	2012
24	Fukuhara M, Arima H, Ninomiya T, Hata J, Yonemoto K, Doi Y, Hirakawa Y, Matsumura K, Kitazono T, Kiyohara Y.	Impact of lower range of prehypertension on cardiovascular events in a general population: the Hisayama Study.	J Hypertens	30	893-900	2012
25	Gotoh S, Doi Y, Hata J, Ninomiya T, Mukai N, Fukuhara M, Kamouchi M, Kitazono T, Kiyohara Y.	Insulin resistance and the development of cardiovascular disease in a Japanese community: the Hisayama Study.	J Atheroscler Thromb	19	977-985	2012
26	Mukai N, Doi Y, Ninomiya T, Hata J, Hirakawa Y, Fukuhara M, Iwase M, Kiyohara Y.	Cut-off values of fasting and post-load plasma glucose and HbA _{1c} for predicting Type 2 diabetes in community-dwelling Japanese subjects: the Hisayama Study.	Diabet Med	29	99-106	2012
27	Doi Y, Ninomiya T, Hata J, Hirakawa Y, Mukai N, Iwase M, Iida M,	Two risk score models for predicting incident type 2 diabetes in Japanese.	Diabet Med	29	107-114	2012

	<u>Kiyohara Y.</u>					
28	Yoshida D, Ninomiya T, Doi Y, Hata J, Fukuhara M, Ikeda F, Mukai N, <u>Kiyohara Y.</u>	Prevalence and causes of functional disability in an elderly general population of Japanese: the Hisayama Study.	<i>J Epidemiol</i>	22	222-229	2012
29	Ikeda F, Ninomiya T, Doi Y, Hata J, Fukuhara M, Matsumoto T, <u>Kiyohara Y.</u>	Smoking cessation improves mortality in Japanese men: the Hisayama Study.	<i>Tob Control</i>	21	416-421	2012
30	Ozawa M, Ninomiya T, Ohara T, Hirakawa Y, Doi Y, Hata J, Uchida K, Shirota T, Kitazono T, <u>Kiyohara Y.</u>	Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: the Hisayama Study.	<i>J Am Geriatr Soc</i>	60	1515-20	2012
31	赤坂憲, 大西浩文, 吉原真由美, 斎藤重幸	端野・壮瞥町研究.	月刊糖尿病	4	484-489	2012
32	斎藤重幸, 吉原真由美	コホート研究からみえる糖尿病と高血圧	糖尿病診療マスター	10	484-489	2012
33	斎藤重幸	日本における動脈硬化性疾患の疫学	プラクティス	30	43-50	2013
34	Misumata K, Saitoh S, Akasaka H, Mitsumata K, Ohnishi H	Effects of hypertension on longitudinal trends in blood pressure and plasma metabolic profile: Mixed-effects model analysis	Hypertens	60	1124-30	2012
35	Furugen M, Saitoh S, Ohnishi H, Akasaka H, Mitsumata K, Chiba M, Furukawa T, Miyazaki Y, Shimamoto K, Miura T	Matsuda-DeFronzo insulin sensitivity index is a better predictor than HOMA-IR of hypertension in Japanese: the Tanno-Sobetsu study	J Hum Hypertens	26	325-333	2012
36	Miyazaki Y, Furugen M, Akasaka H, Saitoh S, Mitsumata K, Miura T	Atherogenic lipid profiles relates to postprandial hyperglycemia and hyperinsulinemia due to whole body insulin resistance in prediabetic subjects	J Diabetes Mellitus.	3	272-279	2012
37	Nagai M, Kuriyama S, Kakizaki M, Ohmori-Matsuda K, Sone T, Hozawa A, Kawado M, Hashimoto S, Tsuji I.	Impact of obesity, overweight and underweight on life expectancy and lifetime medical expenditures: the Ohsaki Cohort Study.	BMJ Open	2	e000940	2012
38	Kakizaki M, Kuriyama S,	Long sleep duration and cause-specific mortality	Journal of Sleep		Epub	2012

	Nakaya N, Sone T, Nagai M, Sugawara Y, Hozawa A, Fukudo S, Tsuji I.	according to physical function and self-rated health: the Ohsaki Cohort Study.	Research		ahead of print	
39	Chou WT, Kakizaki M, Tomata Y, Nagai M, Sugawara Y, Kuriyama S, Tsuji I.	Impact of weight change since age 20 and cardiovascular disease mortality risk.	Circulation Journal	77(3)	679-686	2013
40	Nagai M, Tomata Y, Watanabe T, Kakizaki M, Tsuji I.	Association between sleep duration, weight gain, and obesity for long period.	Sleep Med	14(2)	206-210	2013
41	Hayasaka K, Tomata Y, Aida J, Watanabe T, Kakizaki M, Tsuji I.	Tooth loss and mortality among Japanese elderly: the impact of oral care.	J Am Geriatr Soc.		In press	
42	木幡映美, 寶澤 篤, 柿崎真沙子, 遠又靖丈, 永井雅人, 菅原由美, 栗山進一, 辻一郎.	自覚ストレスと循環器疾患死亡との関連. 大崎国保コホート研究	日本公衆衛生雑誌	59(2)	82-91	2012
43	Nakamura K, Sakurai M, Miura K, Morikawa Y, Nagasawa S, Ishizaki M, Kido T, Naruse Y, Suwazono Y, Nakagawa H.	Serum gamma-glutamyltransferase and the risk of hyperuricemia: a 6-year prospective study in Japanese men.	Horm Metab Res	44(13)	966-974	2012
44	Nakamura K, Sakurai M, Morikawa Y, Miura K, Ishizaki M, Kido T, Naruse Y, Suwazono Y, Nakagawa H.	Overtime work and blood pressure in normotensive Japanese male workers.	Am J Hypertens	25(9)	979-985	2012
45	Sakurai M, Nakamura K, Miura K, Takamura T, Yoshita K, Nagasawa SY, Morikawa Y, Ishizaki M, Kido T, Naruse Y, Suwazono Y, Sasaki S, Nakagawa H.	Self-reported speed of eating and 7-year risk of type 2 diabetes mellitus in middle-aged Japanese men.	Metabolism	61(11)	1566-71	2012
46	Nakamura K, Sakurai M, Miura K, Morikawa Y, Yoshita K, Ishizaki M, Kido T, Naruse Y, Suwazono Y, Nakagawa H.	Alcohol intake and the risk of hyperuricaemia: a 6-year prospective study in Japanese men.	Nutr Metab Cardiovasc Dis	22(11)	989-996	2012

47	<u>山田美智子</u>	認知症の疫学研究 被爆者の追跡調査において	老年期認知症 研究会誌	19 (3)	73-75	2012
48	Grant E J, Ozasa K, Preston D L, Suyama A, Shimizu Y, Sakata R, Sugiyama H, Pham T M, Cologne J, <u>Yamada M</u> , De Roos A J, Kopecky K J, Porter M P, Seixas N, Davis S.	Effects of radiation and lifestyle factors on risks of urothelial carcinoma in the life span study of atomic bomb survivors.	Radiat Res.	178 (1)	86-98	2012
49	<u>Semmens EO</u> , <u>Kopecky KJ</u> , <u>Grant EJ</u> , <u>Mabuchi K</u> , <u>Mathes RW</u> , <u>Nishi N</u> , <u>Sugiyama H</u> , <u>Moriwaki H</u> , <u>Sakata R</u> , <u>Soda M</u> , <u>Kasagi F</u> , <u>Yamada M</u> , <u>Fujiwara S</u> , <u>Akahoshi M</u> , <u>Davis S</u> , <u>Kodama K</u> , <u>Li CI</u> .	Relationship between anthropometric factors, radiation exposure, and colon cancer incidence in the Life Span Study cohort of atomic bomb survivors.	Cancer Causes and Control	24(1)	27-37	2012
50	Tatsukawa Y, Misumi M, <u>Yamada M</u> , Masunari N, Oyama H, Nakanishi S, Fukunaga M, Fujiwara S.	Radiation exposure is associated with body composition in atomic bomb survivors.	Int J Obesity	ijo.2012.193.		2012
51	<u>Yamada M</u> , Shimizu M, Kasagi F, Sasaki H.	Reaction time as a predictor of mortality: The Radiation Effects Research Foundation Adult Health Study.	Psychosom Med	75	154-160	2013
52	Ohsawa M, Tanno K, Itai K, Turin TC, Okamura T, Ogawa A, Ogasawara K, Fujioka T, Onoda T, Yoshida Y, Omama S, Ishibashi Y, Nakamura M, Makita S, Tanaka F, Kuribayashi T, Koyama T, Sakata K, Okayama A.	Comparison of Predictability of Future Cardiovascular Events Between Chronic Kidney Disease (CKD) Stage Based on CKD Epidemiology Collaboration Equation and That Based on Modification of Diet in Renal Disease Equation in the Japanese General Population.	Circulation Journal		In press	—
53	Ohsawa M, Tanno K, Itai K, Turin TC, Okamura T, Ogawa A, Ogasawara K, Fujioka T, Onoda T, Yoshida Y, Omama SI, Ishibashi Y,	Concordance of CKD stages in estimation by the CKD-EPI equation and estimation by the MDRD equation in the Japanese general population: The Iwate KENCO Study.	International of Journal of Cardiology		In press	—

	Nakamura M, Makita S, Tanaka F, Kuribayashi T, Koyama T, Sakata K, Okayama A.					
54	Tanno K, Ohsawa M, Onoda T, Itai K, Sakata K, Tanaka F, Makita S, Nakamura M, Omama S, Ogasawara K, Ogawa A, Ishibashi Y, Kuribayashi T, Koyama T, Okayama A.	poor self-rated health is significantly associated with elevated C-reactive protein levels in women, but not in men, in the Japanese general population.	Journal of Psychosomatic Research	73(3)	225-231	2012
55	Makita S, Onoda T, Ohsawa M, Tanaka F, Segawa T, Takahashi T, Satoh K, Itai K, Tanno K, Sakata K, Omama S, Yoshida Y, Ishibashi Y, Koyama T, Kuribayashi T, Ogasawara K, Ogawa A, Okayama A, Nakamura M.	Influence of mild-to-moderate alcohol consumption on cardiovascular diseases in men from the general population.	Atherosclerosis	224(1)	222-227	2012
56	Onodera M, Nakamura M, Tanaka F, Takahashi T, Makita S, Ishisone T, Ishibashi Y, Itai K, Onoda T, Ohsawa M, Tanno K, Sakata K, Omama S, Ogasawara K, Ogawa A, Kuribayashi T, Sakamaki K, Okayama A.	Plasma B-type natriuretic peptide is useful for cardiovascular risk assessment in community-based diabetes subjects: comparison with albuminuria.	International Heart Journal	53(3)	176-181	2012
57	Umesawa M, Kitamura A, Kiyama M, Okada T, Shimizu Y, Imano H, Ohira T, Nakamura M, Maruyama K, Iso H.	<u>Association between dietary behavior and risk of hypertension among Japanese male workers.</u>	Hypertens Res.		in print	2013
58	Imano H, Iso H, Kiyama M, Yamagishi K, Ohira T, Sato S, Noda H, Maeda K, Okada T, Tanigawa T,	<u>Non-fasting blood glucose and risk of incident coronary heart disease in middle-aged general population: The Circulatory Risk in Communities Study</u>	Prev Med.	55(6)	603-607	2012

	Kitamura A; The CIRCS Investigators.	(CIRCS).				
59	Shimizu Y, Imano H, Ohira T, Kitamura A, Kiyama M, Okada T, Ishikawa Y, Shimamoto T, Yamagishi K, Tanigawa T, Iso H; CIRCS Investigators.	<u>Alkaline Phosphatase and Risk of Stroke Among Japanese: The Circulatory Risk in Communities Study (CIRCS).</u>	J Stroke Cerebrovasc Dis.		in print	2012
60	Ohira T, Maruyama M, Imano H, Kitamura A, Kiyama M, Okada T, Maeda K, Yamagishi K, Noda H, Cui R, Masuda S, Kimura H, Tachikawa K, Ishikawa Y, Iso H.	<u>Risk factors for sudden cardiac death among Japanese: the Circulatory Risk in Communities Study.</u>	J Hypertens	30(6)	1137-43	2012
61	Maruyama M, Ohira T, Imano H, Kitamura A, Kiyama M, Okada T, Maeda K, Yamagishi K, Noda H, Ishikawa Y, Shimamoto T, Iso H.	<u>Trends in sudden cardiac death and its risk factors in Japan from 1981 to 2005: the Circulatory Risk in Communities Study (CIRCS).</u>	BMJ Open.	2(2)	e000573.	2012
62	宇野充子、永野英子、岡田睦美、北村明彦、木山昌彦、岡田武夫、石川善紀	都市部の壮年男性の網膜細動脈硬化の有所見率と関連因子の推移についての検討	人間ドック	27	60-65	2012
63	北村明彦、野田博之、木山昌彦、岡田武夫、中村正和、小野優、梶浦貢、石川善紀、山岸良匡、磯博康、他、CIRCS研究者グループ	特定健診データをもとに脳・心血管疾患発症を予測するツールの開発	Therapeutic Research	33	1541-45	2012

書籍

著者氏名	論文タイトル名	編集者名	書籍名	出版社名	出版地	出版年	ページ
Imano H, Kitamura A, Kiyama M, Ohira T, Cui R, Muraki I, Shimizu Y, Umesawa M, Maeda K, Ido M, Okada T, Nakamura M, Noda H, Yamagishi K, Sato S, Tanigawa T, Ishikawa Y, Iso H.	Usefulness of Skinfold Thickness Measurements for Determining Body Fat Distribution and Disease Risk for Japanese Men and Women	Victor R. Preedy	Handbook of Anthropometry: Physical Measures of Human Form in Health and Disease	Springer-Verlag New York Inc	U.S.A	2012	2667-78

V. 研究成果の刊行物・別刷



ORIGINAL ARTICLE

Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women

Akira Fujiyoshi¹, Takayoshi Ohkubo¹, Katsuyuki Miura¹, Yoshitaka Murakami², Shin-ya Nagasawa³, Tomonori Okamura⁴ and Hirotsugu Ueshima^{1,5}, for the Evidence for Cardiovascular Prevention From Observational Cohorts in Japan (EPOCH-JAPAN) Research Group⁶

Blood pressure (BP) categories defined by systolic BP (SBP) and diastolic BP (DBP) are commonly used. However, the BP category-specific risk of cardiovascular disease (CVD) has not been thoroughly investigated in different age groups. The aim of this study was to assess long-term CVD risk and its impact according to BP categories and age group. Pooling individual data from 10 cohorts, we studied 67 309 Japanese individuals (40–89 years old) who were free of CVD at baseline: we categorized them as belonging to three age groups: 'middle-aged' (40–64 years), 'elderly' (65–74 years) and 'very elderly' (75–89 years). BP was classified according to the 2009 Japanese Society of Hypertension Guidelines. Cox models were used to estimate adjusted hazard ratios for CVD deaths. We observed 1944 CVD deaths over a mean follow-up of 10.2 years. In all age groups, the overall relationship between BP category and CVD risk was positive, with a greater strength observed for younger age groups. We observed a trend of increased risk from SBP/DBP \geq 130/85 mm Hg in the very elderly, and a significant increase from SBP/DBP \geq 120/80 mm Hg in the other age groups. The population attributable fractions (PAFs) of CVD death in reference to the SBP/DBP $<$ 120/80 mm Hg category ranged from 23.4% in the very elderly to 60.3% in the middle-aged. We found an overall graded increase in CVD risk with higher BP category in the very elderly. The PAFs suggest that keeping BP levels low is an important strategy for primary CVD prevention, even in an elderly population.

Hypertension Research (2012) 35, 947–953; doi:10.1038/hr.2012.87; published online 28 June 2012

Keywords: blood pressure category; cardiovascular death; cohort; elderly; population attributable fraction

INTRODUCTION

Epidemiological studies have shown that the effect of both systolic blood pressure (SBP) and diastolic blood pressure (DBP) on the risk of cardiovascular disease (CVD) is continuous and consistent.^{1,2} Because both SBP and DBP are independent predictors of CVD risk,^{3–7} most guidelines for adult blood pressure (BP) management have proposed similar BP categorization systems with regard to the following: (1) BP categories are defined by taking both SBP and DBP into account, and (2) the most favorable BP category is SBP $<$ 120 mm Hg and DBP $<$ 80 mm Hg, irrespective of age.^{8–11}

Although such BP categorization is widely used, there is only limited evidence assessing long-term CVD risk according to BP category, particularly for elderly populations. Given the worldwide trend of aging,¹² assessing the long-term risk of elevated BP and its impact on the aged population is increasingly important from both clinical and public health standpoints. The Framingham Heart Study

(FHS) reported graded increases in major CVD risk across higher BP categories among 1932 participants aged \geq 80 years.¹³ However, the follow-up period was relatively short (mean, 2.7 years).¹³ Therefore, long-term CVD risk was not fully assessed in that study. Other Western studies seeking to assess the BP category-specific risk of CVD events were based on subjects aged \leq 75 years.^{5,14–16} Epidemiological studies on long-term CVD risk among an elderly population have also been limited,^{17,18} and hence needed,¹⁹ in Asia.

The objectives of this study were (1) to estimate long-term CVD mortality risk according to BP categories defined by both SBP and DBP, (2) to examine whether the relationship between BP categories and CVD risk differs according to age group and (3) to compare the impact of increased BP on long-term CVD risk for different age groups by estimating population attributable fractions (PAFs). We focused particularly on an elderly population.

¹Department of Health Science, Shiga University of Medical Science, Otsu, Japan; ²Medical Statistics, Shiga University of Medical Science, Otsu, Japan; ³Department of Epidemiology and Public Health, Kanazawa Medical University, Uchinada, Japan; ⁴Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan and ⁵Lifestyle-Related Disease Prevention Center, Shiga University of Medical Science, Otsu, Japan

⁶For the member list of the EPOCH-JAPAN Research Group, please see the Appendix

Correspondence: Dr A Fujiyoshi, Department of Health Science, Shiga University of Medical Science, Setatsukinowa-cho, Otsu, Shiga 520-2192, Japan.

E-mail: afujiy@belle.shiga-med.ac.jp

Received 5 December 2011; revised 3 March 2012; accepted 19 March 2012; published online 28 June 2012

METHODS

Design

This study is part of a pooling project in which individual participants' data from 13 observational cohorts across Japan were combined. The project was designed to examine the relationship between disease mortality and various exposure factors, including laboratory and lifestyle/behavioral factors. The project is called Evidence for Cardiovascular Prevention from Observational Cohorts in Japan. The inclusion criteria for the cohorts were as follows: collection of health examination measures, follow-up of almost 10 years and more than 1000 participants. Both nationwide and regional cohort studies were included. Other details are reported elsewhere.²⁰

Study population

In all, 10 of 13 cohorts provided data on cause of death ($n=90\,528$). Of those, we used the following exclusion criteria for the present study: age <40 years or >89 years at baseline ($n=10\,528$); history of CVD at baseline ($n=5031$); missing values for SBP, DBP or both ($n=147$); and missing adjusting covariates ($n=7513$). Thus, 67 309 individuals from 10 cohort studies were pooled (Tanno-Sobetsu, Ohsaki, Ohasama, Oyabe, YKK workers, the Radiation Effects Research Foundation cohort, Hsayama, JACC study, NIPPON DATA80 and NIPPON DATA90; see Supplementary Table S1 for the demographics of each cohort).

Death ascertainment

In accordance with the Family Registration Law in Japan, all death certificates are forwarded to the Ministry of Health, Labour and Welfare via the public health center in the area of residence. Registration of death is required by law and believed to be complete. The underlying cause of death is coded according to the International Classification of Disease (ICD) for National Vital Statistics, based on the criteria proposed by the World Health Organization.²¹

Cause of death was sought in great detail using the available sources in each cohort study. In most studies, death certificates were reviewed and/or National Vital Statistics were used after obtaining permission. Other sources used in some studies included autopsy, medical records, health examination and questionnaires. The cause of death was coded based on either ICD-9 or ICD-10. The classification codes used in the study were as follows: death from CVD (390–459 by ICD-9; I00–I99 by ICD-10), total stroke (410–414 or 430–438; I20–I25 or I60–I69), ischemic stroke (433 or 434 or 437.8; I63 or I69.3), intracerebral hemorrhage (431–432; I61 or I69.1), coronary heart disease (410–414; I20–I25) and heart failure (428; I50).

BP measurement

Detailed information on the BP measurement method for each cohort is provided in Supplementary Table S2. BP measurements were obtained using a mercury sphygmomanometer when each participant was in a seated position in all but two cohort studies. In one cohort (Ohasama), an automated device was used.²² In the other study (JACC), the BP values were based on self-recorded values after BP had been measured at a health check-up.²³ In most cohorts, BP was measured once with a participant in a seated position after rest.

BP categories

Participants were categorized according to the modified classification of the 2009 Japanese Society of Hypertension Guidelines (JSH2009).¹⁰ The cutoff values for the BP classification were the same as those in the 2007 Guidelines from the European Society of Hypertension and the European Society of Cardiology (ESH-ESC 2007).⁸ Optimal BP was defined as SBP <120 mmHg and DBP <80 mmHg; the corresponding SBP and DBP values were 120–129 and 80–84 mmHg for normal/non-optimal BP, 130–139 or 85–89 mmHg (whichever was greater) for high-normal BP, 140–159 or 90–99 mmHg for grade I hypertension, 160–179 or 100–109 mmHg for grade II hypertension, and ≥ 180 or ≥ 110 mmHg for grade III hypertension, respectively.

Statistical analysis

We estimated multivariable adjusted hazard ratios (HRs) of death from total CVD and its subtypes for each BP category by Cox proportional hazard models, in reference to the optimal BP category. We constructed two models to adjust for potential confounders. First, we adjusted for age (years), sex and cohort (model 1). Second, we further adjusted for serum total cholesterol (mmol l^{-1}), body mass index (kg m^{-2}), smoking status (current, past, never)²⁴ and alcohol intake (current, past, never) (model 2).

To examine whether the relationship between BP category and risk of CVD death differed according to age, we divided participants into three groups based on their age at baseline: 'middle-aged' represented those 40–64 years old, 'elderly' represented those 65–74 years old and 'very elderly' represented those 75–89 years old. The HR and the corresponding PAF for CVD deaths were estimated for each BP category in each age group. To assess heterogeneity, we assumed a monotonic association between CVD risk and BP category and created pertinent variables. In assessing heterogeneity among cohorts, we created a Forest plot.

PAF was calculated as $\text{pd} \times (\text{RR} - 1) / \text{RR}$, where pd represents the proportion of exposed deaths in a specific BP category and RR is the corresponding multivariable-adjusted HR in reference to the optimal BP category.²⁵ Additionally, we calculated gender-specific mortality risks and PAFs for CVD, total stroke, ischemic stroke, intracerebral hemorrhage, coronary heart disease and heart failure according to the BP category. In testing statistical evidence of interaction between sex and BP category on the effect of CVD risk, we first visually confirmed the overall positive relationship between BP category and CVD risk in both sexes. Then, we created an ordinal variable for BP category and its interaction term with sex, and inserted them in the models.

We performed the following sensitivity analyses: (1) excluding those who died from any cause within the first 3 years as an attempt to eliminate potential reverse causality from low BP;^{26,27} (2) restricting the subjects to non-users of antihypertensive medication at baseline; and (3) adding diabetes mellitus (DM) status (yes or no) to the models for those participants for whom diabetes-defining variables were available ($n=36\,393$). We defined DM as either a fasting glucose level of $\geq 126 \text{ mg dl}^{-1}$ (7.0 mmol l^{-1}), a casual glucose level of $\geq 200 \text{ mg dl}^{-1}$ (11.1 mmol l^{-1}), a Hb A1c level of $\geq 6.5\%$, a history of DM, or taking medication for DM.

All statistical analyses were performed using SAS version 9.13 (SAS Institute, Cary, NC, USA). All of the P values for statistical tests were two-tailed, and $P < 0.05$ were regarded as statistically significant. The study protocol was approved by the internal review board at each study center.

RESULTS

The participants' characteristics at baseline according to BP category are shown in Table 1. The proportion of the participants ($n=67\,309$) in each BP category was 21.9 (optimal BP), 20.2 (normal/non-optimal BP), 21.3 (high-normal BP), 24.9 (grade I hypertension), 9.0 (Grade II hypertension) and 2.7% (grade III hypertension) at baseline. Compared with participants in higher BP categories, those in the optimal BP category tended to be younger and to have a lower body mass index and lower total cholesterol level at baseline. The number of participants categorized as middle-aged, elderly and very elderly was 49 935 (74.2%), 13 707 (20.4%) and 3667 (5.4%), respectively.

During a mean follow-up of 10.2 years, we observed 1944 CVD deaths: 917 from total stroke, 479 from ischemic stroke, 220 from intracerebral hemorrhage, 388 from coronary heart disease and 343 from heart failure in all age groups combined. In the Cox regression models, CVD risk increased almost continuously as the BP category advanced. In disease-specific analyses, the risk of total stroke and coronary heart disease increased similarly as the BP category advanced (see Supplementary Table S3). The PAF estimates indicated that the elimination of normal/non-optimal BP to grade III hypertension could have prevented almost half of the CVD deaths. The results were similar for both sexes, with no statistical evidence of interaction

Table 1 Baseline characteristics of participants according to blood pressure category

Variable	Blood pressure category ^a						
	Optimal (N = 14764)	Normal/non-optimal (N = 13607)	High-normal (N = 14325)	Grade I hypertension (N = 16729)	Grade II hypertension (N = 6079)	Grade III hypertension (N = 1805)	Total (N = 67309)
Women, %	66.1	60.0	56.8	55.4	53.6	51.2	58.7
Age, mean (s.d.), years	53.7 (9.7)	55.5 (10.0)	58.0 (10.0)	59.9 (10.0)	61.5 (10.0)	62.1 (10.4)	57.4 (10.3)
Body mass index, mean (s.d.), kg m ⁻²	22.2 (2.8)	23.0 (2.9)	23.3 (3.0)	23.7 (3.2)	24.0 (3.4)	24.1 (3.6)	23.2 (3.1)
Total cholesterol, mean (s.d.), mmol l ⁻¹ ^b	5.05 (0.91)	5.11 (0.93)	5.21 (0.94)	5.23 (0.97)	5.24 (0.99)	5.27 (1.05)	5.16 (0.95)
<i>Smoking</i>							
Never, %	69.5	66.2	64.4	63.1	61.1	58.0	65.1
Past, %	6.7	9.0	10.5	11.6	12.4	12.9	9.9
Current, %	23.8	24.8	25.2	25.3	26.5	29.1	25.1
<i>Drinking</i>							
Never, %	61.5	57.7	55.6	54.8	53.7	51.5	56.8
Past, %	2.7	2.5	2.8	2.8	3.0	3.2	2.8
Current, %	35.8	39.8	41.6	42.4	43.3	45.3	40.4

^aBlood pressure categories were defined as follows; 'Optimal' as systolic blood pressure <120 mm Hg and diastolic blood pressure <80 mm Hg; the corresponding systolic and diastolic blood pressure values were 120–129 and 80–84 mm Hg for 'Normal/non-optimal,' 130–139 or 85–89 mm Hg (whichever was greater) for 'high-normal,' 140–159 or 90–99 mm Hg for 'grade I hypertension,' 160–179 or 100–109 mm Hg for 'grade II hypertension' and ≥180 or ≥110 mm Hg for 'grade III hypertension, respectively.'

^bThe conversion factor for total cholesterol level from mmol l⁻¹ to mg dl⁻¹ is 38.67.

(*P* for interaction by sex 0.95) (see Supplementary Table S4 and Supplementary Table S5 for sex-specific results).

The crude death rates, adjusted HRs and PAFs according to BP category for each age group are shown in Table 2. The overall relationship between BP category and CVD risk was positive and graded for all age groups, with a greater strength of association observed in the younger group (*P* value for heterogeneity <0.001). For both the middle-aged and elderly groups, compared with individuals in the optimal BP category, the CVD risk increased significantly for those in the normal/non-optimal BP category and continued to increase overall for those in higher BP categories. For the very elderly group, in contrast, both optimal and normal/non-optimal BP categories appeared to have the lowest CVD risk. The PAFs for CVD death in reference to the optimal BP category tended to be greater for younger groups, accounting for 60, 49 and 23% of all CVD deaths in the middle-aged, elderly and very elderly groups, respectively. There is no statistical evidence that these trends differ according to sex in any of the age groups (*P* values for interaction by sex were 0.23, 0.11 and 0.50 for the middle-aged, elderly and very elderly, respectively). (For sex-specific results by age group, see Supplementary Table S6 and Supplementary Table S7).

The Forest plot by cohort indicated an apparently stronger effect of BP in the YKK workers cohort than in other cohorts (Supplementary Figure S1). However, the confidence interval was wide, and the direction of association was the same as for the other cohorts. Furthermore, exclusion of this cohort did not change the results substantially (data not shown). In the Forest plot, we did not observe a clear difference among methods of BP measurement.

In the first sensitivity analysis, which excluded deaths within the first 3 years, the observed association between the BP category and CVD death became stronger for the very elderly group than it was in the main analysis, such that the CVD risk significantly increased for participants in the high-normal BP category and higher categories (Table 3). The results for other age groups were similar to those in the main analysis. In the second sensitivity analysis, which was restricted

to non-users of antihypertensive medication at baseline (29 097 participants, 823 CVD deaths), we observed similar results to the main analysis for all age groups (see Supplementary Table S8). In the third sensitivity analysis, which included DM status in the model, the relationship between BP category and CVD risk was attenuated in both the elderly and very elderly groups, whereas the relationship was slightly strengthened in the middle-aged group (see Supplementary Table S9).

DISCUSSION

This pooled analysis of 10 well-qualified, prospective cohort studies in Japan enabled us to investigate the detailed relationship between BP categories and long-term CVD mortality risk over a broad age range. We found an overall positive relationship for all of the age groups that were studied. In the middle-aged and elderly groups, the risk was lowest for those in the optimal BP category. Importantly, even in the very elderly, the risk appeared to increase from the high-normal BP category to higher BP categories in a graded fashion. The relationship became stronger in this age group when the first 3 years of deaths were excluded. Another important finding of our study is that the impact of elevated BP, as measured by PAF, remained substantial in older groups, suggesting that maintaining optimal BP could have eliminated as many as one-quarter of CVD deaths in the very elderly group and half of those in the elderly group.

In many guidelines, BP categorization involves both SBP and DBP, and the same cutoff values are used irrespective of age.^{8–11} However, only a few studies have examined BP category-specific CVD risk in an elderly population. To our knowledge, this is the first observational study that has demonstrated a long-term CVD risk and its impact according to BP category in a group of very elderly (aged ≥75 years) Asian men and women. From North America/European regions, the FHS showed that major CVD risk increased in a graded fashion with advancing BP category among those aged ≥80 years.¹³ Most other studies from these regions have examined populations aged ≤75 years.^{5,14–16} The FHS observed 336 CVD events among 1932 elderly

Table 2 Cardiovascular death according to blood pressure categories by age group

	Optimal	Normal/non-optimal	High-normal	Grade I hypertension	Grade II hypertension	Grade III hypertension	Total
<i>Very elderly (75–89 years)</i>							
Number at risk	350	483	726	1251	616	241	3667
Person-years	2627	3786	5563	9655	4855	1810	28296
CVD deaths	38	45	105	206	137	60	591
Crude rate ^a	14.46	11.89	18.88	21.34	28.22	33.15	20.89
HR (95% CI) ^b	1	0.83 (0.54–1.28)	1.27 (0.87–1.84)	1.38 (0.97–1.97)	1.46 (1.01–2.12)	1.73 (1.14–2.64)	
PAF (%) ^c	—	–1.6	3.7	9.7	7.3	4.3	23.4
<i>Elderly (65–74 years)</i>							
Number at risk	1880	2227	3105	4290	1735	470	13707
Person-years	16086	19202	26249	38491	15973	4391	120392
CVD deaths	45	96	104	267	146	66	724
Crude rate ^a	2.80	5.00	3.96	6.94	9.14	15.03	6.01
HR (95% CI) ^b	1	1.76 (1.23–2.51)	1.40 (0.99–1.99)	2.20 (1.59–3.03)	2.64 (1.87–3.73)	3.96 (2.67–5.85)	
PAF (%) ^c	—	5.7	4.1	20.1	12.5	6.8	49.3
<i>Middle-aged (40–64 years)</i>							
Number at risk	12534	10897	10494	11188	3728	1094	49935
Person-years	132300	117254	109424	122301	40846	12756	534880
CVD deaths	51	87	102	194	124	71	629
Crude rate ^a	0.39	0.74	0.93	1.59	3.04	5.57	1.18
HR (95% CI) ^b	1	1.77 (1.25–2.51)	1.94 (1.38–2.73)	2.99 (2.17–4.11)	5.23 (3.71–7.35)	8.50 (5.81–12.43)	
PAF (%) ^c	—	6.0	7.9	20.5	15.9	10.0	60.3

Abbreviations: 95% CI, 95% confidence intervals; CVD, cardiovascular disease; HR, hazard ratio; PAF, population attributable fraction.

^aCrude rate was expressed as per 1000 person-year.

^bHazard ratio was adjusted for age, sex, cohort, body mass index (kg m⁻²), total cholesterol (mmol l⁻¹), smoking, and drinking (model 2).

^cPAF estimate was based on the hazard ratio obtained by model 2.

Table 3 Risk of cardiovascular death in the subgroup with those died in the first 3 years excluded

	Optimal	Normal/non-optimal	High-normal	Grade I hypertension	Grade II hypertension	Grade III hypertension	Total
<i>Very elderly (75–89 years)</i>							
No. at risk	296	429	648	1087	518	190	3168
Person-years	2518	3655	5372	9298	4620	1712	27175
CVD deaths	20	34	81	150	94	40	419
Crude rate ^a	7.94	9.3	15.08	16.13	20.35	23.37	15.42
HR ^b	1	1.17 (0.67–2.04)	1.87 (1.14–3.05)	1.91 (1.19–3.07)	1.83 (1.12–3.01)	2.14 (1.23–3.72)	—
<i>Elderly (65–74 years)</i>							
No. at risk	1829	2141	2980	4136	1655	437	13178
Person-years	15970	18998	25923	38126	15789	4315	119120
CVD deaths	39	78	77	223	117	51	585
Crude rate ^a	2.44	4.11	2.97	5.85	7.41	11.82	4.91
HR ^b	1	1.62 (1.10–2.38)	1.19 (0.81–1.76)	2.01 (1.42–2.85)	2.26 (1.55–3.29)	3.28 (2.13–5.04)	—
<i>Middle-aged (40–64 years)</i>							
No. at risk	12440	10811	10400	11057	3657	1066	49431
Person-years	132096	117053	109187	121997	40667	12700	533700
CVD deaths	40	69	87	155	102	60	513
Crude rate ^a	0.3	0.59	0.8	1.27	2.51	4.72	0.96
HR ^b	1	1.75 (1.19–2.60)	2.08 (1.43–3.05)	2.91 (2.03–4.16)	5.21 (3.55–7.64)	8.39 (5.50–12.8)	—

Abbreviations: CVD, cardiovascular disease; HR, hazard ratio.

^aCrude rate was expressed as per 1000 person-year.

^bHazard ratio (95% confidence interval) adjusted for age (years), sex, cohort, body mass index (kg m⁻²), total cholesterol (mmol l⁻¹), smoking (current, never, past) and drinking (current, never, past).

over a mean of 2.7 years.¹³ Compared with the FHS, we observed more than five times as many CVD events among twice as many elderly participants over a mean of 10.2 years. Furthermore, we used six BP categories compared with the four used in the FHS (based on a modified version of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC7) guidelines).⁹ Our categorization allows

us to show finer BP category-specific CVD risks, such as those for normal/non-optimal BP or high-normal BP categories. Nevertheless, our results were broadly consistent with those in the FHS. There are at least two large-scale meta-analyses with pooled data from individual participants that have studied the association between BP and CVD risk: the Prospective Studies Collaboration (PSC)² and the Asia Pacific Cohort Studies Collaboration (APCSC).²⁸ Although our results

are consistent with the results of these studies, our study differs significantly from both of these studies with respect to BP measurements. The PSC and the APCSC used either continuous DBP or SBP alone, whereas we used BP categories that accounted for both SBP and DBP. Several studies from Japan have reported both BP category-specific risk and/or PAF for CVD events.^{29–33} Because of the small sample sizes, however, none of these studies sought detailed estimates for the very elderly population (aged ≥ 75 years), unlike the present study. A recent, large, prospective study from China showed both BP category-specific risk and PAF for CVD events.¹⁸ However, this study provided only limited information with regard to BP category-specific risk and impact on the very elderly population because the authors grouped those aged ≥ 65 years together and used fewer BP categories (a modified JNC7 categorization similar to the FHS) than did our study.

When excluding the first 3 years of death in the very elderly, we observed a stronger overall relationship between BP category and CVD risk, with a significant increase in risk observed for the high-normal BP category and higher categories. This observation may suggest the presence of reverse causality, in which a poor health condition could have caused a lower BP.^{34,35} Exclusion of the first few years of deaths from the analysis was proposed as one way to address reverse causality, particularly when analyzing an elderly population.^{26,27,35} Therefore, the lack of difference in CVD risk between the two lowest BP categories in the very elderly group may be attributable to reverse causality. Another possible explanation is that there is an attenuated strength of association between BP and CVD risk in this age group compared with younger age groups.^{3,28}

We observed a significant difference in the strength of the association between BP and CVD risk (that is, a difference in the relative risk of CVD) according to age group. Such heterogeneity by age in the effect of BP on CVD risk has been observed consistently in many large observational studies.^{18,28,32,36} However, a recent meta-analysis of clinical trials by the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) concluded that there was no evidence of statistical heterogeneity in the effect of BP-lowering therapy on CVD risk between younger and older subjects.³⁷ We speculate that this discrepancy could be due to differences between observational studies and clinical trials and/or due to a lack of statistical power in the BPLTTC study, as the authors of the study have noted.³⁷

Regarding sex-specific differences, we observed that the absolute risk of CVD was generally higher in men than in women in all age groups, whereas the relative risk of CVD according to BP category (expressed as the HR) was similar between men and women (Supplementary Table S4–S7). These findings were consistent with those of previous large observational studies.^{18,38}

The PAF estimates calculated in our study imply that, in a Japanese population, BP has a greater impact on CVD risk than does smoking^{24,39,40} or elevated cholesterol.⁴¹ Combined with the observed lower CVD risks associated with the lower BP categories, the results endorse maintaining a low BP throughout one's life as an important strategy for CVD prevention, both at an individual level and at the population level. It should be emphasized, however, that our results do not necessarily endorse pharmaceutical treatment for hypertension because the study was an observational study among a general population, and not an interventional study on a group of patients. In fact, recent studies indicate that the use of antihypertensive medication is unlikely to lower the risk of CVD to the same level as the risk for those who remain in low BP categories without such treatment.⁴² Furthermore, evidence on pharmaceutical

treatment for hypertension in the very elderly is still limited, as stated in the recent consensus document by the American College of Cardiology Foundation and the American Heart Association.⁴³

Several limitations need to be considered when interpreting our results. First, we did not take into account the use or non-use of antihypertensive medication in the main analyses because of a substantial amount of missing information. However, the sensitivity analysis that was restricted to non-users of such medication at baseline showed similar results to the main analyses for all three age groups. Thus, it is unlikely that this limitation would materially change our inferences. Second, the study was based on a BP measurement on a single occasion, and it did not account for regression dilution bias.² Therefore, the results of the study are likely to underestimate the true association. Third, our estimates in the main analyses were not adjusted for DM. However, we found qualitatively similar results in the sensitivity analysis that adjusted for DM. Therefore, the influence of this limitation on our conclusion would likely be small. One strength of the study is that we pooled data from cohorts with a prospective design with a long follow-up period (over 10 years). Another strength is that the results are likely to be generalizable to a wide age range of adult men and women given that our samples were obtained from across the nation.

In summary, we observed a graded positive trend in CVD mortality risk starting from the high-normal BP category (SBP/DBP $> 130/85$ mm Hg) continuing up to the higher BP categories among the very elderly group and a significant increase in risk starting from the normal/non-optimal BP category (SBP/DBP $> 120/80$ mm Hg) up to the higher categories among the middle-aged and elderly groups. The strength of association between the BP category and CVD risk was attenuated but remained positive and graded in the very elderly. PAFs revealed that keeping BP levels low could prevent one-quarter of CVD deaths in the very elderly and one-half of those in the elderly. These findings suggest that maintaining low BP is an important strategy for primary CVD prevention in an elderly population, even among those aged 75–89 years.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We are grateful to all of the participants in each cohort study. This research was supported by a grant-in-aid from the Ministry of Health, Labour and Welfare, Health and Labor Sciences research grants, Japan (Research on Health Services: H17-Kenkou-007; Comprehensive Research on Cardiovascular Disease and Life-Related Disease: H18-Junkankitou [Seishuu]-Ippan-012; Comprehensive Research on Cardiovascular Disease and Life-Related Disease: H19-Junkankitou [Seishuu]-Ippan-012; Comprehensive Research on Cardiovascular and Life-Style Related Diseases: H20-Junkankitou [Seishuu]-Ippan-013; and Comprehensive Research on Cardiovascular and Life-Style Related Diseases: H23-Junkankitou [Seishuu]-Ippan-005).

- 1 Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. *Arch Intern Med* 1993; **153**: 598–615.
- 2 MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990; **335**: 765–774.
- 3 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; **360**: 1903–1913.
- 4 Miura K, Dyer AR, Greenland P, Daviglius ML, Hill M, Liu K, Garside DB, Stamler J. Pulse pressure compared with other blood pressure indexes in the prediction of 25-year

cardiovascular and all-cause mortality rates: The Chicago Heart Association Detection Project in Industry Study. *Hypertension* 2001; **38**: 232–237.

- 5 Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, Grimm R, Cohen J, Stamler J. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA* 2002; **287**: 2677–2683.
- 6 Okayama A, Kadowaki T, Okamura T, Hayakawa T, Ueshima H. Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80). *J Hypertens* 2006; **24**: 459–462.
- 7 Ueshima H, Iida M, Shimamoto T, Konishi M, Tsujioka K, Tanigaki M, Nakanishi N, Ozawa H, Kojima S, Komachi Y. Multivariate analysis of risk factors for stroke. Eight-year follow-up study of farming villages in Akita, Japan. *Prev Med* 1980; **9**: 722–740.
- 8 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker-Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Manolis A, Nilsson PM, Redon J, Struijker-Boudier HA, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, O'Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten P, Waelder B, Williams B. The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2007; **28**: 1462–1536.
- 9 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr. JL, Jones DW, Materson BJ, Oparil S, Wright Jr. JT, Roccella EJ. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA* 2003; **289**: 2560–2572.
- 10 Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). *Hypertens Res* 2009; **32**: 3–107.
- 11 Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Mc GTS. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. *J Hum Hypertens* 2004; **18**: 139–185.
- 12 United Nations. World population ageing: 1950–2050. In Division Department of Economic and Social Affairs United Nations P (ed), The 2002 World Assembly on Ageing. United Nations Publications: New York 2001.
- 13 Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. *JAMA* 2005; **294**: 466–472.
- 14 Miura K, Daviglius ML, Dyer AR, Liu K, Garside DB, Stamler J, Greenland P. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. *Arch Intern Med* 2001; **161**: 1501–1508.
- 15 Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. *Am J Med* 2006; **119**: 133–141.
- 16 Liszka HA, Mainous 3rd AG, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. *Ann Fam Med* 2005; **3**: 294–299.
- 17 Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, Tanaka K, Ohkubo K, Nakamura H, Abe I, Fujishima M, Iida M. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. *Arch Intern Med* 2003; **163**: 361–366.
- 18 He J, Gu D, Chen J, Wu X, Kelly TN, Huang JF, Chen JC, Chen CS, Bazzano LA, Reynolds K, Whelton PK, Klag MJ. Premature deaths attributable to blood pressure in China: a prospective cohort study. *Lancet* 2009; **374**: 1765–1772.
- 19 Murakami Y. The need for further epidemiologic research on hypertension in Asian regions. *Am J Hypertens* 2009; **22**: 1030.
- 20 Murakami Y, Hozawa A, Okamura T, Ueshima H. Relation of blood pressure and all-cause mortality in 180,000 Japanese participants: pooled analysis of 13 cohort studies. *Hypertension* 2008; **51**: 1483–1491.
- 21 Anonymous. Manual to fill in a death certificate (in Japanese). In The Ministry of Health, Labour, and Welfare (ed), The Ministry of Health, Labour, and Welfare 2010. <http://www.mhlw.go.jp/toukei/manual/dl/manual.pdf>.
- 22 Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognosis of 'masked' hypertension and 'white-coat' hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. *J Am Coll Cardiol* 2005; **46**: 508–515.
- 23 Yamada S, Koizumi A, Iso H, Wada Y, Watanabe Y, Date C, Yamamoto A, Kikuchi S, Inaba Y, Toyoshima H, Kondo T, Tamakoshi A. Risk factors for fatal subarachnoid hemorrhage: the Japan Collaborative Cohort Study. *Stroke* 2003; **34**: 2781–2787.
- 24 Murakami Y, Miura K, Okamura T, Ueshima H. Population attributable numbers and fractions of deaths due to smoking: a pooled analysis of 180,000 Japanese. *Prev Med* 2011; **52**: 60–65.
- 25 Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. *Am J Public Health* 1998; **88**: 15–19.
- 26 Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. *Hypertension* 2005; **45**: 240–245.
- 27 Glynn RJ, Field TS, Rosner B, Hebert PR, Taylor JO, Hennekens CH. Evidence for a positive linear relation between blood pressure and mortality in elderly people. *Lancet* 1995; **345**: 825–829.
- 28 Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S. Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens* 2003; **21**: 707–716.
- 29 Sairenchi T, Iso H, Irie F, Fukasawa N, Yamagishi K, Kanashiki M, Saito Y, Ota H, Nose T. Age-specific relationship between blood pressure and the risk of total and cardiovascular mortality in Japanese men and women. *Hypertens Res* 2005; **28**: 901–909.
- 30 Ikeda A, Iso H, Yamagishi K, Inoue M, Tsugane S. Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC Study. *Am J Hypertens* 2009; **22**: 273–280.
- 31 Kokubo Y, Kamide K, Okamura T, Watanabe M, Higashiyama A, Kawanishi K, Okayama A, Kawano Y. Impact of high-normal blood pressure on the risk of cardiovascular disease in a Japanese urban cohort: the Suita study. *Hypertension* 2008; **52**: 652–659.
- 32 Hozawa A, Kuriyama S, Kakizaki M, Ohmori-Matsuda K, Ohkubo T, Tsuji I. Attributable risk fraction of prehypertension on cardiovascular disease mortality in the Japanese population: the Ohsaki Study. *Am J Hypertens* 2009; **22**: 267–272.
- 33 Iida M, Ueda K, Okayama A, Kodama K, Sawai K, Shibata S, Tanaka S, Keijnai T, Horibe H, Minowa M, Yanagawa H, Hashimoto T. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese – Nippon data 80. *J Hum Hypertens* 2003; **17**: 851–857.
- 34 Staessen J, Bulpitt C, Clement D, De Leeuw P, Fagard R, Fletcher A, Forette F, Leonetti G, Nissinen A, O'Malley K *et al*. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. *BMJ* 1989; **298**: 1552–1556.
- 35 Greenberg JA. Removing confounders from the relationship between mortality risk and systolic blood pressure at low and moderately increased systolic blood pressure. *J Hypertens* 2003; **21**: 49–56.
- 36 Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Prospective studies collaboration. *Lancet* 1995; **346**: 1647–1653.
- 37 Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ* 2008; **336**: 1121–1123.
- 38 Miura K, Nakagawa H, Ohashi Y, Harada A, Taguri M, Kushiro T, Takahashi A, Nishinaga M, Soejima H, Ueshima H. Four blood pressure indexes and the risk of stroke and myocardial infarction in Japanese men and women: a meta-analysis of 16 cohort studies. *Circulation* 2009; **119**: 1892–1898.
- 39 Mannami T, Iso H, Baba S, Sasaki S, Okada K, Konishi M, Tsugane S. Cigarette smoking and risk of stroke and its subtypes among middle-aged Japanese men and women: the JPHC Study Cohort I. *Stroke* 2004; **35**: 1248–1253.
- 40 Baba S, Iso H, Mannami T, Sasaki S, Okada K, Konishi M. Cigarette smoking and risk of coronary heart disease incidence among middle-aged Japanese men and women: the JPHC Study Cohort I. *Eur J Cardiovasc Prev Rehabil* 2006; **13**: 207–213.
- 41 Woodward M, Martiniuk A, Lee CM, Lam TH, Vanderhoorn S, Ueshima H, Fang X, Kim HC, Rodgers A, Patel A, Jamrozik K, Huxley R. Elevated total cholesterol: its prevalence and population attributable fraction for mortality from coronary heart disease and ischaemic stroke in the Asia-Pacific region. *Eur J Cardiovasc Prev Rehabil* 2008; **15**: 397–401.
- 42 Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoki H, Harada A, Murakami Y, Ohashi Y, Ueshima H, Imai Y. Stroke risk and antihypertensive drug treatment in the general population: the Japan arteriosclerosis longitudinal study. *J Hypertens* 2009; **27**: 357–364.
- 43 Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forcica MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation* 2011; **123**: 2434–2506.

Supplementary Information accompanies the paper on Hypertension Research website (<http://www.nature.com/hr>)

APPENDIX

The EPOCH-JAPAN Research Group

Evidence for Cardiovascular Prevention from Observational Cohorts in Japan Research Group is composed of the following individuals: Chairperson: Hirotugu Ueshima (Shiga University of Medical Science); Executive committee: Hirotugu Ueshima (Shiga University of Medical Science), Yutaka Imai (Tohoku University Graduate School of Pharmaceutical Sciences), Fujiko Irie (Ibaraki Prefecture), Hiroyasu Iso (Osaka University Graduate School of Medicine), Yutaka Kiyohara (Kyushu University Graduate School of Medicine), Katsuyuki Miura,

Yoshitaka Murakami (Shiga University of Medical Science), Hideaki Nakagawa (Kanazawa Medical University), Takeo Nakayama (Kyoto University School of Public Health), Tomonori Okamura (Keio University), Akira Okayama (Japan Anti-Tuberculosis Association), Toshimi Sairenchi (Dokkyo Medical University), Shigeyuki Saitoh (Sapporo Medical University), Kiyomi Sakata (Iwate Medical University), Akiko Tamakoshi (Aichi Medical University), Ichiro Tsuji (Tohoku University Graduate School of Medicine) and Michiko Yamada (Radiation Effects Research Foundation).

Influence of Smoking Combined with Another Risk Factor on the Risk of Mortality from Coronary Heart Disease and Stroke: Pooled Analysis of 10 Japanese Cohort Studies

Koshi Nakamura^a Hideaki Nakagawa^a Masaru Sakurai^a Yoshitaka Murakami^b
Fujiko Irie^e Akira Fujiyoshi^c Tomonori Okamura^f Katsuyuki Miura^c
Hirotosugu Ueshima^{c,d} The EPOCH-JAPAN Research Group

^aDepartment of Epidemiology and Public Health, Kanazawa Medical University, Uchinada, Departments of ^bMedical Statistics and ^cHealth Science, and ^dLife-Related Disease Prevention Center, Shiga University of Medical Science, Otsu, ^eDepartment of Health and Welfare, Ibaraki Prefectural Office, Mito, and ^fDepartment of Preventive Medicine and Public Health, Keio University, Tokyo, Japan

Key Words

Smoking • Blood pressure • Cholesterol • Coronary heart disease • Stroke

Abstract

Background: In spite of the importance of a multifactorial approach to preventing cardiovascular disease in smokers, most information on the combined adverse effects of smoking and hypertension or high serum cholesterol on cardiovascular disease has been derived from Western populations, and coronary heart disease was often used as the only endpoint. Therefore, the present large-scale pooled analysis attempted to provide reliable information on the adverse effects of the coexistence of smoking and hypertension or high serum cholesterol on the risk of mortality from coronary heart disease and stroke in both, individuals and the entire population in Japan. **Methods:** A total of 27,385 male and 39,207 female participants aged 40–89 years were enrolled from 10 well-qualified Japanese cohort studies with a mean follow-up of 10.1 years. Hazard ratios and their corresponding 95% confidence intervals in smokers who had hy-

per-tension or high serum cholesterol were estimated for men and women separately using a Cox proportional hazards regression model that included age, body mass index, cohort and either serum total cholesterol or systolic blood pressure as covariates. Fractions of deaths attributable to the coexistence of these risk factors were also calculated. **Results:** The multivariate-adjusted hazard ratios in male and female current smokers with hypertension, compared with those with neither factor were 2.57 (95% confidence intervals, 1.51–4.38) and 6.14 (3.49–10.79) for coronary heart disease, and 3.28 (1.89–5.71) and 1.61 (0.81–3.18) for cerebral infarction, respectively. The fractions of deaths attributable to the coexistence of current smoking and hypertension in men and women were 24.6 and 9.6% for coronary heart disease and 28.1 and 2.0% for cerebral infarction, respectively. Smokers with high serum cholesterol were broadly comparable to hypertensive smokers only with respect to coronary

The members of the EPOCH-JAPAN Research Group are listed in the Appendix.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2012 S. Karger AG, Basel
1015–9770/12/0335–0480\$38.00/0

Accessible online at:
www.karger.com/ced

Koshi Nakamura
Department of Epidemiology and Public Health, Kanazawa Medical University
1-1 Daigaku, Uchinada, Ishikawa 920-0293 (Japan)
Tel. +81 76 218 8093
E-Mail knaka@kanazawa-med.ac.jp

mortality risk; the hazard ratios, compared with those with neither factor were 4.19 (2.33–7.53) for men and 3.90 (1.57–9.67) for women. The fraction of coronary deaths attributable to the coexistence of current smoking and high serum cholesterol was 6.3% in men and 2.2% in women. There was no interaction between smoking habit and blood pressure or serum total cholesterol for these two subtypes in both men and women. **Conclusions:** Particular attention should be given to smokers who have concomitant hypertension or high serum cholesterol for preventing deaths due to cardiovascular disease. From a public health perspective in Japan, priority should be given to hypertensive smokers, since this group makes a large contribution to the burden of both coronary and cerebral infarction deaths.

Copyright © 2012 S. Karger AG, Basel

Introduction

Cardiovascular disease, including coronary heart disease and stroke, is a major cause of death worldwide [1]. This is also true in Japan, where the life expectancy of the population is fairly high [2]. Large-scale cohort studies have demonstrated a causal relationship between smoking and both coronary heart disease and stroke in Asian populations, where intensive tobacco control is an urgent public health policy issue due to the high popularity of smoking among men [3–11]. In fact, these studies have estimated that a major proportion of the morbidity and mortality from cardiovascular disease in Asian men is due to smoking [4, 6–10, 12].

Because of the importance of a multifactorial approach to the prevention of cardiovascular disease in smokers, information is necessary on the adverse effects of smoking combined with another cardiovascular risk factor such as hypertension or high serum cholesterol [13–18]. Hypertension is also a prevalent cardiovascular risk factor [19] and 20–25% of Japanese men are estimated to have both hypertension and a smoking habit [20, 21]. Although high serum cholesterol was less prevalent in Asia than in the West in the past two decades [22], the lipid profile has been worsening in urban areas in Asia due to adoption of a westernized diet that has a high fat content [23, 24]. However, most information on the combined adverse effects of smoking and hypertension or high serum cholesterol has been derived from Western populations, and coronary heart disease was often used as the only endpoint [25–31]. Relevant information is scarce for stroke [30–33], the predominant subtype of cardiovascular disease in Asian populations [23, 24].

The goal of the present large-scale pooled analysis, called Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH-JAPAN), was to provide reliable information on smoking and the risk of mortality from each subtype of cardiovascular disease. In particular, we determined the adverse effects of the coexistence of smoking and hypertension or high serum cholesterol on the risk of death due to cardiovascular disease in both, individuals and the entire population in Japan.

Participants and Methods

Participating Studies

Details of EPOCH-JAPAN are described elsewhere [34, 35]. In brief, EPOCH-JAPAN is a pooled analysis of 13 well-qualified cohort studies in Japan which met the following criteria for inclusion: (1) participation of more than 1,000 individuals in each cohort; (2) follow-up of approximately 10 years; (3) measures of lifestyle, physical conditions and blood biochemistry at study entry, and (4) identification of diseases (mortality and incidence) during follow-up. Individuals aged 40–89 years at study entry were included, and follow-up was terminated at the age of 90 years, because the duration of follow-up varied across the cohorts. Of the 13 cohorts, 10 that had data on disease-specific mortality were used. From 80,000 individuals in 10 cohorts, 13,408 were excluded due to a history of cardiovascular disease ($n = 5,160$) or missing baseline information on sex, smoking habit (never, former or current smoker), body mass index, systolic and diastolic blood pressure, serum total cholesterol or a history of cardiovascular disease ($n = 8,248$). The remaining 66,592 individuals were included in the analyses performed for this report.

Endpoints

The majority of participating studies classified the underlying causes of death according to the ninth revision of the International Classification of Diseases (ICD-9) or the tenth revision of the International Classification of Diseases (ICD-10). Endpoints in this report were cardiovascular diseases (ICD-9 codes 390–459, ICD-10 codes I00–I99), which were further classified into coronary heart disease (ICD-9 codes 410–414, ICD-10 codes I20–I25) and stroke (ICD-9 codes 430–438, ICD-10 codes I60–I69). Stroke was also further classified into cerebral infarction (ICD-9 codes 433, 434, and 437.8a–8b, ICD-10 codes I63 and I69.3) and intracerebral hemorrhage (ICD-9 codes 431–432, ICD-10 codes I61 and I69.1).

Statistical Methods

Initially, to compare the risk of mortality from all cardiovascular diseases as well as each disease subtype, hazard ratios and their corresponding 95% confidence intervals were estimated for current and former smokers, with never-smokers serving as the reference. The hazard ratios were determined from a Cox proportional hazards regression model that included the following variables as covariates: age (years), systolic blood pressure (mm Hg), serum total cholesterol (mmol/l), body mass index (kg/m^2) and cohort. All hazard ratios were estimated for men and women separately in the entire population as well as in two different age groups (40–64 and

65–89 years at study entry). We assessed the heterogeneity for the cardiovascular mortality risk due to smoking between these two age groups for each outcome using likelihood ratio tests [36]. The population attributable fraction (PAF) of deaths was determined when a hazard ratio showed a significant increase in current smokers. The PAF, which represents the contribution of current and former smoking to cardiovascular deaths in the study population, was calculated according to the following formula: $PAF = \text{proportion} \times (\text{hazard ratio} - 1) / \text{hazard ratio}$ [37], using the proportion of deaths among current and former smokers and the hazard ratio.

Next, we examined the adverse effects of smoking, when it was combined with either hypertension or high serum cholesterol, on cardiovascular mortality in both, individuals and in the entire population. To compare the individual risk of cardiovascular mortality among participants grouped according to smoking habit (i.e. never, former or current smoker) and blood pressure (i.e. the absence or presence of hypertension, defined as a systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg), hazard ratios were calculated for each group, with never-smoking without hypertension serving as the reference. Similarly, to compare the cardiovascular mortality risk among participants grouped according to smoking habit and serum total cholesterol (i.e. the absence or presence of high serum cholesterol, defined as a serum total cholesterol ≥ 6.21 mmol/l), hazard ratios were calculated for each group, with never-smoking without high serum cholesterol serving as the reference. We assessed the interaction between smoking habit and blood pressure and the interaction between smoking habit and serum total cholesterol for each outcome using likelihood ratio tests [36]. The PAF was also calculated in a similar manner. All statistical analyses were performed using SAS version 9.13 (SAS Institute Inc., Cary, N.C., USA).

Results

Characteristics of the Study Population

Baseline characteristics of the study participants in each of the 10 cohorts as well as in the overall population are summarized in table 1. The 10 cohorts included 66,592 participants (27,385 men and 39,207 women). The mean age at study entry was 57.7 years in the male participants and 57.3 years in the female participants. The prevalence of never, former and current smoking was 24.3, 22.0 and 53.7% in men and 93.8, 1.3 and 4.9% in women, respectively.

Cardiovascular Disease Deaths

There were a total of 672,031 person-years of follow-up. The mean follow-up period was 10.1 years (9.9 years in men and 10.2 years in women). During follow-up, there were 1,893 deaths due to cardiovascular disease (988 in men and 905 in women) (table 1). These cases included 382 coronary heart disease deaths (216 in men and 166 in women) and 893 stroke deaths (463 in men and 430 in women). Of the documented stroke deaths, 465 deaths

(272 in men and 193 in women) were classified as cerebral infarction and 215 deaths (115 in men and 100 in women) as intracerebral hemorrhage.

Smoking Habits and Cardiovascular Mortality

Tables 2 and 3 show the hazard ratios for the different mortality endpoints in male and female current and former smokers. Current smoking significantly increased the risk of mortality from cardiovascular disease in both men and women even after adjustment for age, body mass index, systolic blood pressure, serum total cholesterol and cohort. The adjusted hazard ratios (95% confidence intervals) were 1.68 (1.42–1.99) for men and 1.63 (1.31–2.05) for women. When cardiovascular disease deaths were classified into subtypes, current smoking in both sexes significantly increased the mortality risk from both coronary heart disease and stroke, especially cerebral infarction. The adjusted hazard ratios in male and female current smokers were 2.07 (1.43–3.01) and 3.03 (1.98–4.65) for coronary heart disease, and 1.82 (1.31–2.53) and 1.31 (0.78–2.19) for cerebral infarction, respectively. These positive associations were more pronounced in participants aged 40–64 than in those aged 65–89 years although current smoking significantly increased the risk of mortality from coronary heart disease and cerebral infarction in both age groups. However, smoking had little effect on the risk of mortality from intracerebral hemorrhage. There was no heterogeneity between these two age groups for any outcome in both men and women.

The fraction of deaths due to cardiovascular disease in men attributable to current and former smoking was 24.4 and 1.7%, respectively. The fraction of deaths due to coronary heart disease was 34.0 and 0.3%, respectively; the fraction of deaths due to cerebral infarction was 25.5 and 7.1%, respectively. The corresponding fraction for each endpoint was greater in men aged 40–64 than in those aged 65–89 years. However, the corresponding fraction for each endpoint was much smaller in women ($\leq 10\%$) than men.

Smoking Habits, Blood Pressure and Cardiovascular Mortality

When current smokers had hypertension (20.5% of all the male and 1.6% of all the female participants), the risk of mortality from cardiovascular disease further increased in both men and women, compared with those that had just one of these risk factors (table 4). The adjusted hazard ratios for cardiovascular disease in male and female current smokers who had hypertension, compared with those that had neither risk factor, were 2.83 (2.17–

Table 1. Baseline characteristics of the entire study population and the participants grouped by cohort (EPOCH-JAPAN)

Cohort name	Geographic location prefecture	Year of baseline survey	Follow-up period years	Participants n	Age at study entry years	Smoking habit						Blood pressure, mm Hg		Serum total mmol/l	BMI kg/m ²
						never-smoker		former smoker		current smoker		systolic	diastolic		
						%	n	%	n	%	n	mean ± SD	mean ± SD		
<i>Men</i>															
Tanno-Sobetsu	Hokkaido	1977	19 ± 4	745	50 ± 7	30.5	227	NA ^a		69.5	518	131 ± 19	82 ± 10	4.81 ± 1.05	23.1 ± 2.7
Osaki	Miyagi	1994	6 ± 1	6,246	62 ± 10	21.6	1,350	29.6	1,848	48.8	3,048	132 ± 17	80 ± 11	5.02 ± 0.87	23.6 ± 2.9
Ohasama	Iwate	1997	10 ± 3	877	59 ± 11	49.6	435	NA ^a		50.4	442	134 ± 17	76 ± 11	4.84 ± 0.89	23.1 ± 2.8
Oyabe	Ishikawa	1988	10 ± 2	1,461	60 ± 10	45.2	661	NA ^a		54.8	800	131 ± 20	79 ± 11	4.69 ± 0.85	22.6 ± 2.7
YKK workers	Toyama	1990	11 ± 3	1,970	47 ± 5	27.7	545	15.4	303	57.0	1,122	121 ± 16	76 ± 12	5.21 ± 0.88	22.7 ± 2.6
RERF cohort	Hiroshima	1986	15 ± 4	650	55 ± 11	14.6	95	28.0	182	57.4	373	122 ± 13	79 ± 8	5.11 ± 0.91	21.8 ± 2.7
Hisayama	Fukuoka	1988	11 ± 3	1,107	58 ± 12	20.4	226	29.5	327	50.1	554	135 ± 20	81 ± 11	5.09 ± 1.07	22.8 ± 3.0
JACC study	Nationwide ^b	1988-90	9 ± 2	9,176	58 ± 10	22.9	2,100	24.0	2,206	53.1	4,870	135 ± 19	81 ± 11	4.86 ± 0.90	22.8 ± 2.8
NIPPON DATA80	Nationwide ^b	1980	16 ± 5	2,741	55 ± 11	17.9	492	20.4	558	61.7	1,691	142 ± 21	85 ± 12	4.83 ± 0.87	22.5 ± 2.9
NIPPON DATA90	Nationwide ^b	1990	9 ± 2	2,412	57 ± 11	21.7	524	24.8	597	53.5	1,291	140 ± 20	85 ± 12	5.14 ± 0.96	23.0 ± 3.0
Total			10 ± 4	27,385	58 ± 11	24.3	6,655	22.0	6,021	53.7	14,709	134 ± 19	81 ± 12	4.95 ± 0.91	23.0 ± 2.9
<i>Women</i>															
Tanno-Sobetsu	Hokkaido	1977	19 ± 4	867	50 ± 7	92.5	802	NA ^a		7.5	65	133 ± 20	82 ± 10	5.02 ± 0.91	24.2 ± 3.4
Osaki	Miyagi	1994	6 ± 1	6,967	61 ± 9	93.4	6,509	1.7	115	4.9	343	130 ± 18	77 ± 11	5.48 ± 0.88	24.1 ± 3.2
Ohasama	Iwate	1997	11 ± 2	1,363	58 ± 9	97.5	1,329	NA ^a		2.5	34	129 ± 16	73 ± 11	5.3 ± 0.93	23.9 ± 3.3
Oyabe	Ishikawa	1988	10 ± 1	3,166	58 ± 10	97.4	3,085	NA ^a		2.6	81	126 ± 20	75 ± 11	5.23 ± 0.94	23.2 ± 3.1
YKK workers	Toyama	1990	11 ± 3	1,036	47 ± 5	98.9	1,025	0.2	2	0.9	9	117 ± 16	72 ± 12	5.31 ± 0.95	22.3 ± 2.7
RERF cohort	Hiroshima	1986	16 ± 3	1,447	58 ± 10	87.1	1,261	2.4	35	10.4	151	121 ± 14	76 ± 8	5.57 ± 0.99	22.3 ± 3.3
Hisayama	Fukuoka	1988	11 ± 2	1,515	59 ± 12	91.0	1,379	2.1	31	6.9	105	133 ± 22	76 ± 11	5.53 ± 1.07	22.9 ± 3.3
JACC study	Nationwide ^b	1988-90	10 ± 2	16,151	56 ± 9	95.3	15,394	1.2	188	3.5	569	132 ± 19	78 ± 11	5.26 ± 0.94	23.3 ± 3.2
NIPPON DATA80	Nationwide ^b	1980	17 ± 4	3,420	56 ± 11	89.4	3,057	2.1	73	8.5	290	138 ± 22	81 ± 12	5.05 ± 0.87	23.1 ± 3.4
NIPPON DATA90	Nationwide ^b	1990	10 ± 1	3,275	57 ± 12	89.3	2,925	2.2	72	8.5	278	137 ± 20	81 ± 12	5.49 ± 0.98	23.1 ± 3.3
Total			10 ± 4	39,207	57 ± 10	93.8	36,766	1.3	516	4.9	1,925	131 ± 20	78 ± 11	5.32 ± 0.95	23.4 ± 3.2

BMI = Body mass index; SD = standard deviation; NA = not available.

^a Former smoking was included in never-smoking in 3 cohort studies (Tanno-Sobetsu, Ohasama and Oyabe).

^b Study participants in 3 nationwide cohort studies were selected from all areas of Japan.

Table 2. Hazard ratios for cardiovascular mortality and the PAF of deaths in 27,385 men grouped according to age and smoking habit (EPOCH-JAPAN)

	Overall men			40–64 years			65–89 years		
	never-smoker	former smoker	current smoker	never-smoker	former smoker	current smoker	never-smoker	former smoker	current smoker
Participants, n	6,655	6,021	14,709	4,878	3,627	11,106	1,777	2,394	3,603
Person-years of follow-up	65,929	55,712	148,830	51,280	37,221	120,330	14,649	18,491	28,499
Cardiovascular disease									
Cases, n	188	204	596	47	49	250	141	155	346
Adjusted HR ^a	1.00	1.09	1.68	1.00	1.20	2.08	1.00	1.08	1.57
95% CI	ref.	0.89–1.34	1.42–1.99	ref.	0.80–1.80	1.52–2.86	ref.	0.85–1.37	1.28–1.92
PAF ^b , %		1.7	24.4		2.4	37.5		1.8	19.6
				p value for heterogeneity ^c = 0.61					
Coronary heart disease									
Cases, n	36	38	142	12	9	64	24	29	78
Adjusted HR ^a	1.00	1.02	2.07	1.00	0.83	2.25	1.00	1.11	2.01
95% CI	ref.	0.64–1.63	1.43–3.01	ref.	0.34–1.98	1.21–4.21	ref.	0.63–1.96	1.26–3.22
PAF ^b , %		0.3	34.0		NC	41.8		2.2	29.9
				p value for heterogeneity ^c = 0.35					
Stroke									
Cases, n	92	97	274	17	20	115	75	77	159
Adjusted HR ^a	1.00	1.09	1.60	1.00	1.40	2.58	1.00	1.02	1.36
95% CI	ref.	0.81–1.46	1.25–2.04	ref.	0.72–2.71	1.54–4.33	ref.	0.73–1.43	1.02–1.81
PAF ^b , %		1.7	22.2		3.8	46.3		0.5	13.5
				p value for heterogeneity ^c = 0.18					
Cerebral infarction									
Cases, n	50	68	154	4	9	48	46	59	106
Adjusted HR ^a	1.00	1.40	1.82	1.00	2.32	4.44	1.00	1.28	1.53
95% CI	ref.	0.96–2.04	1.31–2.53	ref.	0.70–7.68	1.58–12.45	ref.	0.85–1.91	1.07–2.18
PAF ^b , %		7.1	25.5		8.4	61.0		6.1	17.4
				p value for heterogeneity ^c = 0.42					
Intracerebral hemorrhage									
Cases, n	33	18	64	10	6	34	23	12	30
Adjusted HR ^a	1.00	0.57	0.93	1.00	0.86	1.35	1.00	0.51	0.78
95% CI	ref.	0.32–1.04	0.60–1.43	ref.	0.30–2.45	0.66–2.78	ref.	0.24–1.05	0.44–1.38
PAF ^b , %		NC	NC		NC	NC		NC	NC
				p value for heterogeneity ^c = 0.66					

HR = Hazard ratio; CI = confidence interval; NC = not calculated; ref. = reference.

^a From a Cox proportional hazards regression model with multivariate adjustment for age, systolic blood pressure, serum total cholesterol, body mass index and cohort. ^b PAFs were calculated as proportion \times (HR – 1)/HR, using the proportion of deaths in each smoking group and the HR. ^c The heterogeneity for the cardiovascular mortality risk due to smoking between the younger group and the older group was assessed using likelihood ratio tests.

3.69) for men and 2.70 (2.00–3.64) for women. A similar pattern was observed for both coronary heart disease and stroke, especially cerebral infarction. The adjusted hazard ratios in male and female current smokers who had hypertension were 2.57 (1.51–4.38) and 6.14 (3.49–10.79) for coronary heart disease, and 3.28 (1.89–5.71) and 1.61 (0.81–3.18) for cerebral infarction, respectively. There was

no interaction between smoking habit and blood pressure for coronary heart disease and cerebral infarction in both men and women, whereas there was relevant interaction for intracerebral hemorrhage in women but not in men.

The fraction of deaths due to cardiovascular disease attributable to the coexistence of current smoking and hypertension was 25.7% for men and 3.8% for women.

Table 3. Hazard ratios for cardiovascular mortality and the PAF of deaths in 39,207 women grouped according to age and smoking habit (EPOCH-JAPAN)

	Overall women			40–64 years			65–89 years		
	never-smoker	former smoker	current smoker	never-smoker	former smoke	current smoker	never-smoker	former smoker	current smoker
Participants, n	36,766	516	1,925	27,909	296	1,462	8,857	220	220
Person-years of follow-up	375,816	5,055	20,689	296,791	3,178	16,460	16,460	1,877	4,230
Cardiovascular disease									
Cases, n	791	27	87	234	6	25	557	21	62
Adjusted HR ^a	1.00	1.41	1.63	1.00	2.08	1.86	1.00	1.33	1.60
95% CI	ref.	0.96–2.08	1.31–2.05	ref.	0.92–4.70	1.22–2.82	ref.	0.86–2.06	1.22–2.08
PAF ^b , %		0.9	3.7		1.2	4.4		0.8	3.6
p value for heterogeneity ^c = 0.73									
Coronary heart disease									
Cases, n	133	7	26	39	2	8	94	5	18
Adjusted HR ^a	1.00	2.18	3.03	1.00	4.25	3.52	1.00	1.90	2.89
95% CI	ref.	1.01–4.70	1.98–4.65	ref.	1.01–17.94	1.61–7.68	ref.	0.77–4.71	1.73–4.83
PAF ^b , %		2.3	10.5		3.1	11.7		2.0	10.1
p value for heterogeneity ^c = 0.67									
Stroke									
Cases, n	385	12	33	124	3	12	261	9	21
Adjusted HR ^a	1.00	1.35	1.31	1.00	2.11	1.79	1.00	1.25	1.17
95% CI	ref.	0.76–2.41	0.92–1.88	ref.	0.67–6.68	0.98–3.26	ref.	0.64–2.43	0.75–1.83
PAF ^b , %		NC	NC		NC	NC		NC	NC
p value for heterogeneity ^c = 0.55									
Cerebral infarction									
Cases, n	169	8	16	35	3	1	134	5	15
Adjusted HR ^a	1.00	1.79	1.31	1.00	5.62	0.44	1.00	1.30	1.52
95% CI	ref.	0.87–3.65	0.78–2.19	ref.	1.71–18.52	0.06–3.19	ref.	0.53–3.18	0.88–2.61
PAF ^b , %		NC	NC		NC	NC		NC	NC
p value for heterogeneity ^c = 0.06									
Intracerebral hemorrhage									
Cases, n	94	2	4	37	0	3	57	2	1
Adjusted HR ^a	1.00	1.01	0.68	1.00	0.00	1.52	1.00	1.44	0.27
95% CI	ref.	0.25–4.14	0.25–1.87	ref.		0.46–5.01	ref.	0.35–5.94	0.04–1.92
PAF ^b , %		NC	NC		NC	NC		NC	NC
p value for heterogeneity ^c = 0.12									

HR = Hazard ratio; CI = confidence interval; NC = not calculated; ref. = reference.

^a From a Cox proportional hazards regression model with multivariate adjustment for age, systolic blood pressure, serum total cholesterol, body mass index and cohort. ^b PAFs were calculated as proportion × (HR – 1)/HR, using the proportion of deaths in each smoking group and the HR. ^c The heterogeneity for the cardiovascular mortality risk due to smoking between the younger group and the older group was assessed using likelihood ratio tests.

The corresponding fraction of deaths due to coronary heart disease was 24.6% for men and 9.6% for women, whereas the corresponding fraction of deaths due to cerebral infarction was 28.1% for men and 2.0% for women.

Smoking Habits, Serum Total Cholesterol and Cardiovascular Mortality

The coexistence of current smoking and high serum cholesterol (4.2% of all the male and 0.8% of all the female

participants) further increased the cardiovascular mortality risk in both men and women, compared with the presence of either risk factor (table 5). The adjusted hazard ratios for cardiovascular disease in participants with both risk factors was higher than in participants with neither risk factor: 1.94 (1.39–2.71) for men and 1.87 (1.14–3.09) for women. A similar pattern was observed for coronary heart disease but not for stroke. The adjusted hazard ratios for coronary heart disease in men and women